To evaluate the clinical effectiveness of HIFU therapy for early localized prostate cancer. HIFU therapy is applied as primary treatment for low and intermediate risk localized prostate cancer (T1-2 NxM0) in patients older than 70 years, and for local recurrence of prostate cancer after radiotherapy failure
eNrNWNFu2jAUfecrorwnISsrMAWqjbUbUquytmjTXpBJbohZsNNrm0K/fg7QjU7J2ppa6iO2Offa9/jcE0cnq0XuLAEF5aznhn7TdYDFPKFs1nPHN2dexz3pN6I5WZL9ZR2/OQk7oevEORGi55bz/hQIE/6Pi/PPoBEA3X7Difh0DrF8tE5JmvtficguSFGucaIlp4mzAJnxpOcWSm5GnUhI1Hn07zj+EgWJIQp2I/uz80lrfzwKSrBnoCoBeE7YrBIUmBFmrBCByQGRMOO4roRO48m7TrvVaZmlTcUVCK4whhGR2Qj5kiaQVEciuQCjIOldcg24zEGWQSrBg3m8EEbgZE5WV3A7rE76o54dyJX0ml54HLbet7udbrd1HBqFwr2jqiaP3kQQT8Jm2G03jwJgQUZnmUeZBCaoXHspjzVREk/lEokGY4mX0VTpcfRkBp5EIHKha+7x1Mt5THJ6r5cXyIXULPBiwmJAw0qPOEqSW6oxFYPHbLUUB+H2SS4lVBQ5WftzUZgeFUGipwG1ptjbSLmDG9Qql+sz+wefqTwPXpj1eKdBljIuJW6gOStrpGh8bXoQA65vyKq+ombqKVc7LlIQrwd7z1l15xipaU5jU4HUEqZAyPHVsF4f3660fCICxmhPW75TlvA78fqatc8RS9kXG9n9b/M+PjK+kD81HWt636lCXkCgtYyKQyRqyFJ+qDhphldDPfD7jVJ7Y+tKRKgxdhND1dOcfvCh1m6NvRu5nagE/XJ6Y0q2bwpwfb35WQlNk94fmpi1BBt9RlO7NvGXX5StWjzD8h+1u00zSmO1GGVSFuJDEGREeILog/JTfONtZ8832Pt0sWJOtmZtK96WUp9ue/Lza216bZ+yLofa8d3/d7a/MoZEBQfUYavw1nR4ePr60v7Xi1tLe/RIiuyF2fhmIilnthyYmlYiHtZMdF3ZGWpxuExTWvOaVMvLKNi+ZPUbUVC+YvUbvwHn5V3J
bdb1ac8L5Zq00Vd3